The ARRIVE study plan is a freely available resource to assess the rigour and improve the transparency of planned animal research.
421 results
£10M will be available to support interdisciplinary research clusters.
We have made the first Network primer awards to our 3Rs Network members to establish collaborations and apply 3Rs technologies to new research questions.
Explore the evolving relationship between genetic modification and the 3Rs over the past two decades in our article in the Genetics Society magazine.
Analysis led by the NC3Rs aims to inform new endocrine disruption testing requirements in the EU to avoid substantially increasing animal use and resource.
Our total commitment for project grants over the past twenty years has now surpassed £50M, supporting 3Rs method development, characterisation and dissemination.
Our Experimental Design Assistant (EDA) helps you to design robust and meaningful animal experiments. With a wealth of information, features and tools, here are our tips to help you make the most of the EDA.
An in vitro assay to test follicle-stimulating hormone potency has been recognised in the annual NC3Rs Prize which is co-funded by GSK.
In collaboration with the Only Good Antibodies community we are improving the integrity and reproducibility of biomedical research that relies on commercial antibodies.
Our latest impact stories feature three replacement approaches developed through NC3Rs funding that were the first in vitro models validated to replace animal use for specific experiments in their research areas.
Two new funding opportunities to develop new approach methodologies for avian toxicity or an easy-to-use shelter to improve post-operative recovery and monitoring of rodents.
We are launching a new funding opportunity through a strategic collaboration with BBSRC to help researchers commercialise their 3Rs tools and technologies.
NC3Rs new Partnership and Impact awards offer up to £200k to support the transfer of 3Rs approaches into new research organisations.
NC3Rs Programme Manager Dr Elliot Lilley reflects on the united vision that drove the success of our project to embed the 3Rs in quality, safety and efficacy testing of vaccines and biological therapeutics.
We are partnering with Pint of Science to invite you to learn more about the science behind replacing animals in research.
Hear from the NC3Rs NAMs Advisory Group as they discuss their recent paper on how to overcome the hurdles to embedding new approach methodologies (NAMs) in chemical and drug safety assessment.
Bringing together oncology researchers to establish collaborations and catalyse the uptake of 3Rs technologies for cancer research.
We have published a report to increase the uptake of non-animal derived antibodies and non-antibody affinity reagents by the research community.
A new paper makes recommendations for dose selection in developmental and reproductive toxicity studies to avoid unnecessary animal suffering, reduce animal use and maintain the highest standards of human health protection.
Working directly with scientists, technicians and research institutions to accelerate the uptake of the 3Rs, our new regional training offering is available free of charge across the UK.
